Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26326310 | 0.90 | — | — | |
| SCHEMBL26326308 | 0.89 | XPO1 (0.36) | HDAC1HDAC6 | |
| SCHEMBL3848312 | 0.84 | CYP11B1 (0.38) | CYP11B1CYP11B2SMN1; SMN2ADORA2AADORA1 | |
| SCHEMBL8387437 | 0.79 | CYP11B1 (0.39) | CYP11B1CYP11B2TP53MAPTSMN1; SMN2 | |
| SCHEMBL9086670 | 0.78 | NPC1 (0.38) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL16965270 | 0.77 | SYK (0.57) | — | |
| SCHEMBL23116712 | 0.74 | — | — | |
| SCHEMBL29666388 | 0.74 | — | — | |
| SCHEMBL29666427 | 0.74 | XPO1 (0.36) | ADORA2AADORA1HDAC1HDAC6 | |
| SCHEMBL23116709 | 0.74 | XPO1 (0.36) | ADORA2AADORA1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-09-28 | — | — | US | disclosed |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XPOT, XPO1, XPO5 | CYP11B1 628/4885CYP11B2 1030/4885TP53 1019/4885 |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPOT, XPO1, XPO5 | CYP11B1 628/4885CYP11B2 1030/4885TP53 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.